A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
about
Update on treatment of light chain amyloidosisA rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Amyloidosis: pathogenesis and new therapeutic options.Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativDiscordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsLenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.Light chain amyloidosis 2012: a new era.Future directions in the clinical management of amyloid light-chain amyloidosis.Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.New and developing therapies for AL amyloidosis.Disease burden of systemic light-chain amyloidosis: a systematic literature review.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
P2860
Q26829735-F7B4A249-3CD1-487B-A6CC-23BFC9BEB734Q33802749-6A8D989B-8A40-40DB-8FE1-9DCBC2F950AAQ34353682-CFAC8DE3-39EB-4F87-990A-665411282974Q34448455-DC0CEB88-4D82-4B95-B72C-2066D3758CC7Q35111771-D16157DA-1C05-44D0-9182-EB5C3157A2ADQ35571048-5C6CAD81-CF69-469D-9F33-9D8C7AC4E7A7Q36950813-542A5CAD-0217-454C-A5EC-C2329FCC8A3EQ37212712-6861C307-EDF8-47A8-8D52-AED7A99A5E61Q37676296-632AF083-9A49-4031-B21F-5ADEA33E4FAAQ38072108-B858205E-D27E-4637-BA92-829E28CBAFDEQ38172998-3A383E6F-45AA-4CFA-8A3B-E2F705B880D5Q38376616-26E08FAB-A188-460B-9B2D-CE091EBBABBDQ38411566-5F10B509-226E-4B1C-ACFE-C58A47B3000BQ38600436-8F5716B3-ADDD-4546-AE1E-B22D9CC4BD27Q38614967-43119688-7C01-4CB6-9743-A0F46D37FFE2Q38779623-A333E02F-027E-4243-90B4-232759E1D569Q38917828-FCDE9122-5FA2-4003-B76D-30E1239C110BQ38928383-67396793-E827-44C7-98AA-0BA0539EAB36Q41593651-1C95F5BD-73CF-4A32-BF0D-600F866D668DQ41645533-210B678A-DC4D-491D-A3BA-49A303828D0FQ43057972-73AFC677-A46E-40D4-9971-BEEF8CF4A8F9Q44060632-6B6167BC-D16D-427D-9378-ABA4FD1CB5BDQ46728404-F393B050-6F6E-4C78-8E00-E7F0CB2E2E59Q49691497-6F72A9DA-F222-481D-956E-F0AC6E1B4F44
P2860
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A phase II trial of cyclophosp ...... patients with AL amyloidosis.
@en
type
label
A phase II trial of cyclophosp ...... patients with AL amyloidosis.
@en
prefLabel
A phase II trial of cyclophosp ...... patients with AL amyloidosis.
@en
P2860
P50
P1433
P1476
A phase II trial of cyclophosp ...... d patients with AL amyloidosis
@en
P2093
Andrea Foli
Paola Russo
P2860
P304
P356
10.3324/HAEMATOL.2012.073593
P577
2012-09-14T00:00:00Z